Skip to content

Earnings call

Narayana Hrudayalaya Q4 FY26 earnings call

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company is not giving guidance; the 20% consolidated margin, affected by one-time U.K. acquisition costs, normalizes to slightly over 22%, which is the base for improvement. The company has 45 beds in bone marrow transplant in Bangalore and 10 such beds in Kolkata. The company does almost 100 robotic cardiac surgery cases per month in Bangalore. In the Caribbean, there are only two private healthcare assets at a scale of 100 million plus, and assets below that scale do not make much sense for Narayana Hrudayalaya Limited to work with.

The numbers management gave

Results

  • The company does almost 100 robotic cardiac surgery cases per month in Bangalore.
    Show source
    So if you see that we have gone very high in the robotic cardiac surgery, we do almost 100 cases per month.
  • The company did around 160 percutaneous aortic valve reimplantation procedures in the Bangalore facility alone.
    Show source
    We did around 160 procedures of that nature in the Bangalore facility alone.
  • Clinics and insurance business reported INR 66 crores loss in FY26.
    Show source
    If you look at the clinics and insurance losses, it has remained flat around INR 66 crores loss in FY26.
  • Clinics take an 18-month period to turn around; clinics set up about 2 years back have broken even, and the losses are mainly due to corporate overheads incurred to sustain the integrated care infrastructure.
    Show source
    So the clinics that we set up about 2 years back, they have broken even and the losses that you're seeing are mainly because of the corporate overheads that are being incurred to sustain the integrated care infrastructure.
  • The Indian business margin was 21.5% for the same quarter last year and 25.1% now.
    Show source
    That has been consistently increasing, like, let's say, for last year same quarter, you reported 21.5% margin, and now it's 25.1%.
  • Loss ratio is approximately 110% to 112%, measured as claims paid divided by premiums collected net of reinsurance; for a year 1 insurance book, price increases midyear and exiting some accounts are expected to help it settle.
    Show source
    So it's approximately about 110% to 112% is the loss ratio, which is essentially claims paid divided by premiums collected net of reinsurance.
Show 8 more statements

Results

  • The company operated overall overheads of about 28% without U.K.; with U.K., the overhead figure will be 23%.
    Show source
    And with U.K., we'll see a 23% number.
  • The acquisition-related costs caused almost 200 bps of the 500 bps margin dilution and are one-time costs that will not repeat; the effective dilution is about 300 bps, resulting in a normalized margin of around 22%.
    Show source
    So normalized margin around 22%.
  • The company typically operates at 60% to 65% occupancy, but does not report occupancy and does not believe occupancy or ARPOB is a correct measure of performance; it considers ARPIP and throughput the right measures.
    Show source
    Page 18 of 23 Narayana Hrudayalaya Limited May 26, 2026 The right measure is ARPIP, which we report and also throughput, which is evident from the way we are able to do incremental volumes through the same facility.
  • Of the INR127 crores, INR 94 crores was a dividend received from Cayman in India; this dividend is eliminated in consolidation, and the remainder is the group's other income.
    Show source
    Sandhya J: That INR127 crores has INR 94 crores of dividend that has been received from Cayman to India.
  • With 10% revenue growth, Narayana Hrudayalaya's overheads increased by about 8%, reflecting variable costs moving with revenue, higher power costs and minimum wages, underlying cost inflation absorbed through revenue-growth leverage, and one-time costs from a merger process.
    Show source
    Sandhya J: See, actually, with the 10% revenue growth, our overheads has gone up by about 8%.
  • Mumbai hospital broke even in Quarter 4; Narayana Hrudayalaya is working toward starting the adult program in Mumbai and is in advanced discussions with the trust for approval, and believes the program will turn around the hospital's profitability profile.
    Show source
    We do believe that we will be able to turn around the profitability profile of the Mumbai hospital once the adult program comes in.
  • The U.K. acquisition diluted Narayana Hrudayalaya's FY '26 consolidated PAT, return on equity and return on capital.
    Show source
    As far as the next question, which is looking at the FY '26 consolidated PAT, it is been diluted by U.K. So return on equity and return on capital are being diluted as well.
  • The company does the highest number of paediatric bone marrow transplants in its non-cardiac work.
    Show source
    And if you look at the other non-cardiac work, we do the highest number of paediatric bone marrow transplants as well.

What it expects ahead

What management expects

  • The company is not giving guidance; the 20% consolidated margin, affected by one-time U.K. acquisition costs, normalizes to slightly over 22%, which is the base for improvement.
    Show source
    Sandhya J: Yes, we are not giving any guidance, but what we have explained is that the 20% margin, which has come at a consol level has one-timer impact on it because of the acquisition costs relating to U.K., which normalizes to slightly over 22%.
  • The company intends to add new clinics in the coming year, which will bring cash burns, while increased leverage of fixed costs will moderate some of the cash burn.
    Show source
    Now as we add new clinics, which we intend to do in the coming year, we will have cash burns coming in the new clinics, though the leverage that we will get for the fixed costs will also increase.
  • A similar run rate of cash burn will continue on Narayana Hrudayalaya's clinics going into next year because it has a significant ambition for growth of clinics in its core geographies.
    Show source
    So you have to assume that a similar run rate of cash burn will continue on the clinics going into next year as well because we still have a significant ambition in terms of growth of clinics in our core geographies.
  • The company is not planning to enter the insurance business in the U.K.
    Show source
    So just to clarify, for U.K., we're not planning to get into the insurance business.
  • The company expects to continue its ARPOB performance so far, with healthy ARPOB growth over the past couple of years based on efficiencies in reducing length of stay and changing payer mix.
    Show source
    We expect to be able to continue the performance that we've had so far.
  • The company Limited will dilute ROCE for growth during its current expansion phase.
    Show source
    So overall, we are going through a phase where we will be diluting ROCE for growth.
Show 1 more statement

What management expects

  • The company is trying to maintain the pace of business growth and expects a jump when new hospitals are added, while not giving guidance. Replaced by a later filing.
    Show source
    There will be a jump when new hospitals get added.

What it is building and selling

Projects and capacity

  • The company has 45 beds in bone marrow transplant in Bangalore and 10 such beds in Kolkata.
    Show source
    If we have 45 beds in bone marrow transplant in Bangalore, we have 10 such beds in Kolkata.
  • Kolkata has around 30% of the scale of the infrastructure of the Bangalore campus.
    Show source
    So that's the difference around 30% of the scale of the infrastructure is what we have in Kolkata compared to the Bangalore campus.
  • The company has 11 clinics in Bangalore and will expand there; in FY27 it will also expand to Calcutta, with a plan to double its current number of clinics, paced against property acquisition, rent negotiations, fit-outs and maintaining steady cash losses.
    Show source
    We have a plan to double the number of clinics that we currently have, but the speed at which we do it would be balanced on the other side against the acquisition of those properties, negotiating the rent, doing the fit-outs and also maintaining a steady amount of cash losses in the business so that we don't go overboard.
  • The company said election-related issues made it impossible to bring construction workers in for a large amount of time, and delays in obtaining permissions also delayed project commissioning; the FY '28 goal remains, and work can pick up now that things have normalized.
    Show source
    The FY '28 goal still remains the case, and a lot of this work can pick up now that things have normalized.
  • The company plans to spend about 3000 crores in India over the next three years across Greenfield, Brownfield, O&M and acquisitions.
    Show source
    We're putting in INR 3,000 crores in India.
  • Rajarhat project will have many integrated quaternary care facility all in one place.
    Show source
    So that's where when we come up with the Rajarhat project, we will have many integrated quaternary care facility all in one place.
Show 3 more statements

Demand and pricing

  • In the Caribbean, there are only two private healthcare assets at a scale of 100 million plus, and assets below that scale do not make much sense for Narayana Hrudayalaya Limited to work with.
    Show source
    We have put in USD 100 million capex and came in for expansion.
  • Year-on-year rack rate and price increases hover in the low to mid-single digits.
    Show source
    But the one thing to note is that year-on- year, the rack rate and the price increases that we take hover in the low to mid-single digits.

Segments

  • The company is currently operating insurance only in India and the Cayman Islands.
    Show source
    We're currently only operating insurance in India and the Cayman Islands.

Risks, rules and outside factors

Outside factors

  • Construction cost is 60% higher than it was 5 years ago, reflecting post-pandemic-related cost increases beyond Narayana Hrudayalaya's control.
    Show source
    One is just naturally construction cost today is 60% higher than it was 5 years ago.
  • The cost of land acquisition is much higher in big cities, but it is a one-time cost. Replaced by a later filing.
    Show source
    Cost of land acquisition, yes, that is much higher in the big cities, but that is a one-time cost.

Everything else said on the call

Group structure

  • The subject discussed with Sajal Kapoor is a 100% subsidiary.
    Show source
    It is a 100% subsidiary.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Sajal Kapoor: So Hrudayalaya, where it's a partnership model, the listed entity doesn't own it outright today. But they are on our hospital premises and they use the brand, et cetera?

    Answer, viren shetty

    Viren Shetty: So we run pharmacies in all our hospitals and in all our clinics. We run it -- when it's in the hospital, it runs under the P&L of the hospital. When it's in the clinics, it runs under the NHIC for now. They fulfil the dispensing functions for people walking in, people who come with a prescription, people who walk into our clinics, avail services, we are able to offer them pharmacy services. As part of the integrated care model, this is also something that's of tremendous value for patients. And for those who subscribe to our Arya plan, they get access to home delivery services, where on our own expense, we undertake the expense of taking the medicine to their house as well as doing pickups and so on. Page 2 of 23 Narayana Hrudayalaya Limited May 26, 2026 But we are not yet, at this point, thinking to create a separate stand-alone pharmacy vertical similar to, say, Apollo Pharmacy, which only does retail pharmacy in a branded franchise model on a stand-alone basis.

    Answer, viren shetty

    For us, the pharmacy is the primary fulfilment center for our internal needs in the clinic and hospital.

  2. Question

    Sajal Kapoor: Yes, yes...

    Answer, viren shetty

    Viren Shetty: This is a subsidiary of the listed entity. All the related party companies that you see are owned by the listed company.

  3. Question

    Sajal Kapoor: Okay. So it's not very clear in -- Viren, in the annual report. I think we need to just clarify a bit because I -- so I run a Substack channel, and I'm very active on Twitter. I get a lot of these queries because I've been a 10-year-old shareholder here in Narayana, right? So there's a... Sandhya J: 100% subsidiary, Sajal, actually, this has been clarified in the annual report.

    Answer, sandhya j

    It is a 100% subsidiary. What we can do, Sajal, is that given that many of these are little fundamentals, we can take a separate call with you from the IR team. Page 3 of 23 Narayana Hrudayalaya Limited May 26, 2026 Sajal Kapoor: That's very helpful, Sandhya...

  4. Question

    Sajal Kapoor: Yes, I've got many more strategic questions, but in the interest of the time, I will drop you an e-mail and we can -- or the IR team rather, and then we can take it from there. Thank you so much for your time.

    Answer, viren shetty

    Viren Shetty: Yes. Dr. Rupert will answer this. Dr. Emmanuel Rupert: So if you really -- we have been mentioning over the last 3, 4 quarters about the complexities of the cases that is being delivered at Bangalore. So if you see that we have gone very high in the robotic cardiac surgery, we do almost 100 cases per month. Many competing hospitals do probably that in 1 to 2 months. I mean, 1 to 2 in a year, we do it in a month. That's the scale at which we operate.

    Answer, viren shetty

    So are the percutaneous aortic valve reimplantation, which is suggested a couple of hours in the cath lab for an aortic valve replacement, which generally used to happen with the surgical program is happening in the cath lab nowadays, and we do a very large number. We did around 160 procedures of that nature in the Bangalore facility alone. And if you look at the other non-cardiac work, we do the highest number of paediatric bone marrow transplants as well. So the complexities of work that happens here is quite on the very high quaternary range, and that brings in the financial gains which you are talking about. Kolkata journey - if you look at the kind of infrastructure that we have in Bangalore, it's extremely large facilities which we have to support the scale of the clinical work. Kolkata, we have limited in scale because we can't expand within that small campus of around 3.5 acres in RN Tagore Hospital. So that's where when we come up with the Rajarhat project, we will have many integrated quaternary care facility all in one place.

    Answer, viren shetty

    That's where we are. If we have 45 beds in bone marrow transplant in Bangalore, we have 10 such beds in Kolkata. So that's the difference around 30% of the scale of the infrastructure is what we have in Kolkata compared to the Bangalore campus. Prithivaj: Okay. Got it. My second question on India business. If you look at the clinics and insurance losses, it has remained flat around INR 66 crores loss in FY26.

    Answer, sandhya j

    Sandhya J: So it is a factor of the number of new clinics that we are setting up. If we have more clinics coming in, every clinic takes an 18-month period to turn around. So the clinics that we set up about 2 years back, they have broken even and the losses that you're seeing are mainly because of the corporate overheads that are being incurred to sustain the integrated care infrastructure. Now as we add new clinics, which we intend to do in the coming year, we will have cash burns coming in the new clinics, though the leverage that we will get for the fixed costs will also increase. So therefore, some of the cash burn will moderate because of that. So you have to assume that a similar run rate of cash burn will continue on the clinics going into next year as well because we still have a significant ambition in terms of growth of clinics in our core geographies.

    Answer, viren shetty

    Viren Shetty: What we are doing is a little bit of consolidation and a few of the corporate overheads can be worked in a way that we share resources with the parent and we'll be demerging the clinic business into the core that should help with a lot of that. But we've seen a lot of positive aspects of running these clinics. We are accessing patients domestically that historically would never consider coming to Narayana. We've generated a lot of inpatient referrals of fairly advanced therapies for the main hospital. So they act as an excellent feeder for all the hospitals and build up that long-term relationship for patients who tomorrow will subscribe to our One Health plans insurance plans and then become Narayana Health customers. Prithviraj: Got it. One final question on India business.

    Answer, viren shetty

    If you look at the India business, say, hospitals margins, I think over the last couple of quarters margins have expanded significantly. Do you think there is still scope for further margin expansion in India hospital business?

    Answer, viren shetty

    Viren Shetty: As you know, we don't give guidance on those. But a lot of the things we put in place that have brought us to this journey still have room for growth and there's still a fair amount of work that we've put in place that we'll start to see. But of course you have to balance that out against the new center losses that will start coming in from the mid- to end of this financial year and going forward. So one would temper the other. Prithviraj: Understood. Fine. I will join back in the queue for international questions.

  5. Question

    Sir, as a customer and as a patient, we appreciate it. Sir, regarding the business updates, sir, when do we expect the breakeven to be achieved in the insurance business? And sir, on the U.K. side of things, are we planning to get into insurance there as well?

    Answer, viren shetty

    Viren Shetty: Sure. I'll answer the India insurance business and Anesh will answer for the U.K. business. For India and the insurance business, this is still the early days. We have a very reasonable control overall claims ratio. What's happening right now is that once you combine it with the expenses, it is what's causing the losses, but this is to be expected for any new business that is being built up here. We've had a lot of positive momentum in growing our group business with small and medium enterprises. And we're doing a lot of things on automation to bring the overall admin cost down.

    Answer, viren shetty

    So it definitely will start to reduce over the coming years. But at this point, we can't give a date for when the losses would subside. Anesh, would you be able to address whether we're planning in U.K. Anesh Shetty: No, plans for that.

    Answer, viren shetty

    Viren Shetty: Yes. So just to clarify, for U.K., we're not planning to get into the insurance business. We're currently only operating insurance in India and the Cayman Islands.

    Answer, viren shetty

    Viren Shetty: No. Like I said, we don't have retail pharmacies. All our pharmacies are fulfilling internal demand. What we do have is a very large purchasing network and a formulary that is able to get very good deals with suppliers. There are certain antibiotics that we're talking with suppliers. These are still in the very early stages, but these wouldn't be branded per se. These are just unbranded generic medicines that are coming directly from the manufacturer to our facility. And these are meant mostly for inpatient activities, not for selling in the outside market.

  6. Question

    Shashwat Singh: Okay, sir. And sir, why do we not consider that?

    Answer, viren shetty

    Viren Shetty: We don't have sufficient scale at which it makes sense. If a manufacturer has to put a dedicated line for you and the packaging and so on, that's only in your brand, they will not take returns. And there is a certain amount of volume guarantee you would need to give them, which from an outpatient perspective, does not make sense for us.

  7. Question

    Shashwat Singh: Okay, sir. And sir, going forward, what would be the ARPOB growth that we are expecting?

    Answer, viren shetty

    Viren Shetty: Again, without giving forward guidance, we have seen healthy ARPOB growth over the past couple of years based on the efficiencies on reducing length of stay and changing the payer mix. We expect to be able to continue the performance that we've had so far. But the one thing to note is that year-on- year, the rack rate and the price increases that we take hover in the low to mid-single digits. Page 6 of 23 Narayana Hrudayalaya Limited May 26, 2026 Moderator: Shashwat, I request you to join back the queue.

  8. Question

    Japreet Singh: I mean this you have to increase our efficiencies and technology, increase the payer mix. What led you to believe that you will turn this acquisition into value creation?

    Answer, viren shetty

    Viren Shetty: Okay. Fine. Anesh, if you can just talk about the things.

    Answer, anesh shetty

    Anesh Shetty: Yes. Thank you for your question, Japreet. So essentially, we have two prime areas of focus. The first is to increase the proportion of patients coming from private sources that is self-pay or private insurance. Those patients inherently pay more for the same service. The second is an implementation of our entire technology platform that will allow us to meaningfully lower the cost base for all operational processes, similar to what we've done in the Cayman Islands.

    Answer, cayman singh

    Japreet Singh: What is the purpose behind this acquisition motive.

    Answer, anesh shetty

    Anesh Shetty: So once we had stabilized our operations in Cayman, we were looking for a second jurisdiction or a second country with a larger base and a larger potential because our software platform, our technology and the systems we had developed to make Cayman a very profitable operation are scalable in other markets as well. And outside India, in certain European, U.K., British mature markets, the acquisition multiples are quite reasonable relative to the opportunity we have to lower the cost base and improve earnings.

  9. Question

    Japreet Singh: There are also some other risks like cultural difference like, culture in Narayana will be different to what practice plus culture and your resources will also get diverted, your focus will also change. That's obvious and integration risks are also there. So how do you see these risks?

    Answer, anesh shetty

    Anesh Shetty: Yes, definitely, you are right. These are all things we have to be aware of and cautious about with any acquisition in a different geography, there are cultural integration risks, understanding local nuances. These are things we have to work through.

    Answer, anesh shetty

    Anesh Shetty: On a more sustainable steady-state basis, what we can say at a high level is that now that we are running the company as an independent entity, there are some costs and cost increases with regards to certain IT costs, vendor costs, etcetera, compared to when it was part of a broader company. At the same time, now that it is part of NH, there are cost synergies as well that we bring to the table. So, as Sandhya mentioned, in a few quarters, the overs and unders should neutralize, and we will get a better sense of the trajectory improvement in earnings. Raman: Understood, sir. Thank you for that. And my second question is with respect to the margins of the Indian business. That has been consistently increasing, like, let's say, for last year same quarter, you reported 21.5% margin, and now it's 25.1%.

  10. Question

    Akshay Thakur: Yes. Thanks for taking my question and congratulations on good numbers. My question is related to the new capex, which you have announced. So this capex is on the higher end as compared to the old Narayana days. So my question is, so you are expanding in core areas like within the city limits, not like early days. So we being a low-cost model, low volume player, we try to cut down our expenses on opex and capex front. Now the capex front has increased as compared to the previous model, so the only impact would be on the opex front. So, how do we plan to follow the same model, but at the different locations, which is on the higher expensive capex per bed?

    Answer, viren shetty

    Viren Shetty: Yes. So, the capex is higher for 2 reasons. One is just naturally construction cost today is 60% higher than it was 5 years ago. These are post-pandemic-related cost increases that is beyond our control. So no matter where you are building, if you're building in the most small town in India or if you're building the largest capital of the country, the construction cost has gone up significantly. So that cost remains the same wherever it goes. Cost of land acquisition, yes, that is much higher in the big cities, but that is a one-time cost.

Show 3 more questions
  1. Question

    Prithvi Raj: Is it possible for you to give the claims ratio here on a higher trend?

    Answer, anesh shetty

    Anesh Shetty: I would say the loss ratio, I mean, we don't disclose it specifically, but if you look at the CIMA statistics, you can find out. So it's approximately about 110% to 112% is the loss ratio, which is essentially claims paid divided by premiums collected net of reinsurance. So for a year 1 insurance book, that's not very bad. I mean it's not great, but it's not horrible. So with the price increases midyear as well as exiting some accounts, we hope that, that does settle in.

  2. Question

    Akshay Thakur: Can you also share your plans for the clinics? How much do you want to expand? What capex to spend on those and strategy behind them?

    Answer, viren shetty

    Viren Shetty: Yes. The clinics, we are 11 clinics in Bangalore. We will be expanding in Bangalore. And this year, meaning FY27, we will also be expanding to Calcutta. We have a plan to double the number of clinics that we currently have, but the speed at which we do it would be balanced on the other side against the acquisition of those properties, negotiating the rent, doing the fit-outs and also maintaining a steady amount of cash losses in the business so that we don't go overboard. But the clinics are a very important channel for us to be able to be closer to our patients.

  3. Question

    Sashwat Singh: Okay. So that help’s sir. That is all. Thank you.

    Answer, sandhya j

    Sandhya J: Yes. So, in health care, it's not SG&A, but it is more overheads as we would call it. So, U.K. comes in at an overhead structure, which is lower than the group overhead structure. So, we believe that whatever numbers you're seeing right now, so without U.K., we were operating overall, all overheads put together at about 28%. And with U.K., we'll see a 23% number.

    Answer, sandhya j

    Sandhya J: Yes. Just one -- just quickly on the 500 bps, almost 200 bps dilution has come because of the costs relating to the acquisition itself. Those are one-timers in nature, and those will not repeat. So, the effective dilution is about 300 bps. So normalized margin around 22%. And Anesh, I think, spoke about the various plans that we have to improve the payer mix and improve the mix. U.K. will not come to the levels of India or Cayman.

    Answer, sandhya j

    Sandhya J: See, we don't report out occupancy, but we typically operate between 60% to 65% in terms of occupancy. We do not believe that either ARPOB or occupancy is a correct measure of performance. Page 18 of 23 Narayana Hrudayalaya Limited May 26, 2026 The right measure is ARPIP, which we report and also throughput, which is evident from the way we are able to do incremental volumes through the same facility.

    Answer, sandhya j

    Sandhya J: That INR127 crores has INR 94 crores of dividend that has been received from Cayman to India. So, because of that, you are seeing that number not coming in consol -- consol that intercompany gets eliminated. The rest of it is the real other income for the group.

    Answer, sandhya j

    Sandhya J: See, actually, with the 10% revenue growth, our overheads has gone up by about 8%. There are a few factors to this. There is a certain part of the overheads, which is purely variable in nature, and therefore, that moves in tandem with the revenue. Now in addition, it is a very high inflationary situation that we are working with. Power costs have gone up across the board and minimum wages have gone up across the board. So, there are a lot of underlying cost inflation, which we are absorbing in our overheads with the leverage that is being created with the revenue growth. In addition, there are some one-time costs in there because we are going through a certain merger process.

    Answer, sandhya j

    Sandhya J: Thank you, Venkatesh. Nishant Singh: The other part of the question was -- private pay was 7% of PPG revenue at acquisition. Where is it now? And what is the realistic 2-year target? Maybe Anesh can take this.

    Answer, nishant singh

    Nishant Singh: Next question is Kolkata being one of the core geography with 26% revenue share that has grown only at 5%, 6%. Is it because of the lower international patient? If yes, how much is the international patient share in Kolkata geography? Do we expect the growth to kind of come in line with the Bangalore growth?

    Answer, nishant singh

    Nishant Singh: The next question is FY26 greenfield capex is only INR 109 crores against INR 424 crores planned, 75% to 74% miss. What specifically caused the slippage? And does the FY28 commissioning timeline for Rajarhat, HSR, Raipur, Bangalore still hold?

    Answer, viren shetty

    Viren Shetty: Lot of the project has started. The miss was due to a lot of the election-related issues in that it was impossible to get construction workers to come for a large amount of time. A few delays in commissioning the project for not getting permissions and so on. The FY '28 goal still remains the case, and a lot of this work can pick up now that things have normalized.

    Answer, sandhya j

    Sandhya J: Yes, we are not giving any guidance, but what we have explained is that the 20% margin, which has come at a consol level has one-timer impact on it because of the acquisition costs relating to U.K., which normalizes to slightly over 22%. So that is the base at which we are starting, and we have to work with improving on that.

    Answer, nishant singh

    Nishant Singh: The next is based on the disclosures in Slide 22 of the deck, the total capex for projects proposed INR 3,000 crores. Same slide also mentions greenfield organic capex is INR 460 crores. All projects are expected to be commissioned by FY '28, '29. Does it mean FY '28, '29, we'll have INR 1,000 crores each?

    Answer, viren shetty

    Viren Shetty: Again, we're not giving guidance, but we're trying to maintain the pace of growth in our business. There will be a jump when new hospitals get added.

    Answer, sandhya j

    Sandhya. Sandhya J: So, Mumbai has broken even in Quarter 4. We are working towards the adult program starting in Mumbai. We are in stages of discussion with the trust for approval, and it's in advanced stages of conversation. We do believe that we will be able to turn around the profitability profile of the Mumbai hospital once the adult program comes in. As far as the next question, which is looking at the FY '26 consolidated PAT, it is been diluted by U.K. So return on equity and return on capital are being diluted as well. So you want to understand the 3- year IRR or acquisition case.

    Answer, sandhya j

    So when we did our acquisition call, we had given a very detailed rationale and the business case for the acquisition, the valuation metrics and what levers we think are available for us to be able to create value with this acquisition. So, I would request you to refer to the transcript of that call in which a very detailed explanation is available. At a very broad level, we are going through an expansion phase right now. We have put in USD 100 million capex and came in for expansion. We're putting in INR 3,000 crores in India. So overall, we are going through a phase where we will be diluting ROCE for growth. And eventually, this will come back because the mode of acquisition which we have chosen, mode of investment which we have chosen are longer-term ROCE accretive.

Questions about this call

When was the Narayana Hrudayalaya Q4 FY26 earnings call transcript filed?
Narayana Hrudayalaya filed the transcript with the exchange on 2 Jun 2026. This page is built from that transcript.
What does this page list?
33 statements from the transcript across 7 topics, 22 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 13 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Narayana Hrudayalaya Q4 FY26 concall: what the company said · DalalOS